Melanoma Risk Quadrupled by Moles
the Cancer Therapy Advisor take:
According to a new study, having moles can increase a patient's risk of developing melanoma by four times. In the study conducted by researchers from University of Melbourne in Melbourne, Australia, University of Oxford in Oxford, United Kingdom, and the Epworth HealthCare in Victoria, Australia, researched identified 271,656 patients who had moles on their skin during a hospital visit and 10,130,417 patients who did not.
They found that the group with moles were about 4.6 times more likely to develop melanoma, the deadliest skin cancer, compared with the group with no moles.
Furthermore, researchers found that having moles on the trunk of the body increased the risk of both melanoma on the trunk and elsewhere on the body. Specifically, patients with moles on the trunk of their bodies were nine times more likely to develop melanoma of the trunk and 5.6 times more likely to develop the disease elsewhere.
Researchers warn patients that about half of melanomas develop in pre-existing moles, and in those cases, there is typically an area of the mole that changes color. They also advise patients to see a physician if the moles in changes in color, shape, or size.
Moles can quadruple your risk of developing melanoma, the deadliest type of skin cancer.
Having moles on your skin can quadruple your risk of developing melanoma, the deadliest type of skin cancer, according to a study released this week by experts at the University of Melbourne, University of Oxford, and the Epworth HealthCare.
The researchers compared the medical records of two groups of people – 271,656 for whom moles had been recorded during a hospital visit for any condition, and 10,130,417 who did not have moles recorded. Comparison of the two groups revealed over all, the group with moles were approximately 4.6 times more likely to develop melanoma than the group with no recorded moles.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models